Abstract
We have used single-cell imaging of fura-2-loaded cells to examine the Ca2+ signals evoked by activation of 5-hydroxytryptamine type 3 (5-HT3) receptors in undifferentiated N1E-115 neuroblastoma cells and in human embryonic kidney (HEK) 293 cells transfected with either of the two cloned 5-HT3 receptor subunits. The selective 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide (mCPBG) caused a concentration-dependent increase in the cytoplasmic Ca2+ concentration ([Ca2+]i) in N1E-115 cells and in HEK 293 cells transfected with either the 5-HT3 A subunit or the 5-HT3 As subunit. In each case, the [Ca2+]i rise was steeply dependent on the mCPBG concentration (nH = 2-4) and abolished by removal of extracellular Ca2+ or addition of ondansetron. Pretreatment of N1E-115 cells with thapsigargin, caffeine, and ryanodine to deplete intracellular Ca2+ stores had no effect on the mCPBG-evoked Ca2+ signals, indicating that they result entirely from stimulated Ca2+ entry. The steep concentration-effect curves therefore are not a consequence of amplification of Ca2+ influx by Ca(2+)-induced Ca2+ release from intracellular stores and probably reflect cooperative activation of 5-HT3 receptors by mCPBG. Depolarization of transfected HEK 293 cells with medium containing increased K+ concentrations invariably failed to evoke an increase in [Ca2+]i, confirming the absence of voltage-gated Ca2+ channels and indicating that the mCPBG-evoked rise in [Ca2+]i results from Ca2+ permeation of 5-HT3 receptors. However, in N1E-115 cells and transfected HEK 293 cells, both extracellular Na+ and K+ substantially inhibited the Ca2+ influx evoked by activation of 5-HT3 receptors, possibly by inhibition of agonist binding or by competition with Ca2+ for permeation of the channel. We conclude that 5-HT3 receptors are Ca2+ permeant, that the Ca2+ influx is sufficient to generate a significant rise in [Ca2+]i, and that, because the A and As subunits behave similarly, conflicting electrophysiological analyses of Ca2+ currents cannot be explained by differences between these two subunits.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|